Malaysian Medical Centre Granted Exclusive Global Rights For HITV Treatment

KUALA LUMPUR, Aug 11 (Bernama) -- A private medical centre has been entrusted by a Japanese research centre to expand the use of its Hasumi Immuno-Therapeutic Vaccine (HITV) for the treatment of cancer in Malaysia as well as other overseas markets. Mahameru International Medical Centre managing director Dr Beh Chor Khim said the firm had been granted exclusive global licensing rights for intellectual property as well as the current and future research and development of Hasumi International Research Foundation (HIRF). He said this in a press statement issued in conjunction with the joint venture signed between himself and managing director of HIRF Minoru Komura here Monday night, which was witnessed by former prime minister Dr Mahathir Mohamad (picture). Dr Beh said through the agreement, Kuala Lumpur would be the first city outside of Japan to provide a one-stop Hasumi Immunotherapy centre, which has recorded a high success rate in the treatment of stage four cancer. It has been reported that the treatment was discovered by Dr Hasumi Kenichiro in 2005, and is now known as Hasumi Immuno-Therapeutic Vaccine (HITV), which works by adjusting and upgrading the patient's own immune system to target cancer cells. Over 500 patients with late stage cancer treated with HITV in Hasumi's clinic in Tokyo have been said to have shown high complete response and partial response rates. However, the treatment cannot be considered as a cure as it can only be done if cancerous tumours can be identified, and it is meant to complement rather than replace conventional treatment. MIMC, which was setup in 2007 for the treatment of ambulatory medical facilities, had teamed up with Dr Hasumi to provide HITV protocol to cancer patients in Malaysia since 2010. HIRF was founded as a non-profit organisation by Dr Kenichiro Hasumi, aimed to conduct and support scientific research to find a cure for many types of cancers, especially using immunotherapy. (photoBERNAMA) -- BERNAMA